FierceBiotechOriginal article
{"a":[{"_":"AstraZeneca pens $2.1B Sino deal for challenger to Merck’s COPD drug Ohtuvayre","$":{"href":"/biotech/astrazeneca-pays-sino-200m-challenger-mercks-copd-drug-ohtuvayre","hreflang":"en"}}]}
OhtuvayreSino COPD drug candidatePositive
AI Analysis
Summary
AstraZeneca acquired ex-China rights to a late-phase COPD drug candidate from Sino Biopharmaceutical for $200 million upfront, positioning it as a challenger to Merck's Ohtuvayre.
Importance:7/10
Sentiment:
0.60
M&ACOPDlate-phaseex-China rightsAstraZenecaSino Biopharmaceutical
Related Companies
Read the original article
Published by FierceBiotech on July 8, 2026 3:41 AM